Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017

Jessica S. Donington; Young Tae Kim; Betty Tong; Andre L. Moreira; Jamie Bessich; Kathleen D. Weiss; Yolonda L. Colson; Dennis Wigle; Raymond U. Osarogiagbon; Jeffrey Zweig; Heather Wakelee; Justin Blasberg; Megan Daly; Leah Backhus; Paul Van Schil

doi:10.1016/j.jtho.2018.04.002

Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017

Jessica S. Donington, Young Tae Kim, Betty Tong, Andre L. Moreira, Jamie Bessich, Kathleen D. Weiss, Yolonda L. Colson, Dennis Wigle, Raymond U. Osarogiagbon, Jeffrey Zweig, Heather Wakelee, Justin Blasberg, Megan Daly, Leah Backhus, Paul Van Schil

General Thoracic Surgery

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

The landscape of care for early-stage non–small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. We have an increased understanding of the diversity of early-stage disease and how to better tailor treatments to make them more tolerable without impacting efficacy. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. The source for information includes large academic meetings, the published literature, or novel unpublished data from other international oncology assemblies.

Original language	English (US)
Pages (from-to)	767-778
Number of pages	12
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/j.jtho.2018.04.002
State	Published - Jun 2018

Keywords

Adjuvant therapy
Intraoperative lymph node evaluation
Non–small cell lung cancer
Pathology
Radiotherapy
Screening
Sublobar resection
Surgery
Surveillance

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2018.04.002

Cite this

Donington, J. S., Kim, Y. T., Tong, B., Moreira, A. L., Bessich, J., Weiss, K. D., Colson, Y. L., Wigle, D., Osarogiagbon, R. U., Zweig, J., Wakelee, H., Blasberg, J., Daly, M., Backhus, L., & Van Schil, P. (2018). Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017. Journal of Thoracic Oncology, 13(6), 767-778. https://doi.org/10.1016/j.jtho.2018.04.002

@article{20198a34fed2449ca894991607e8a793,

title = "Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017",

abstract = "The landscape of care for early-stage non–small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. We have an increased understanding of the diversity of early-stage disease and how to better tailor treatments to make them more tolerable without impacting efficacy. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. The source for information includes large academic meetings, the published literature, or novel unpublished data from other international oncology assemblies.",

keywords = "Adjuvant therapy, Intraoperative lymph node evaluation, Non–small cell lung cancer, Pathology, Radiotherapy, Screening, Sublobar resection, Surgery, Surveillance",

author = "Donington, {Jessica S.} and Kim, {Young Tae} and Betty Tong and Moreira, {Andre L.} and Jamie Bessich and Weiss, {Kathleen D.} and Colson, {Yolonda L.} and Dennis Wigle and Osarogiagbon, {Raymond U.} and Jeffrey Zweig and Heather Wakelee and Justin Blasberg and Megan Daly and Leah Backhus and {Van Schil}, Paul",

note = "Funding Information: Disclosure: Dr. Donington has received personal fees from Astra Zeneca. Dr. Tong has received personal fees from Medtronic. Dr. Moreira has received support from Genentech. Drs. Weiss and Colson have received grants from the National Institutes of Health, Brigham and Women{\textquoteright}s Hospital Advanced Training in Surgical Oncology T32 Fellowship (5T32CA009535). Dr. Osarogiagbon has a patent application pending for a lymph node specimen collection kit. Dr. Wakelee has received fees from Peregrine, ACEA, Novartis, Pfizer, Roche/Genetech, and Helsinn; and has received grants from Novartis, Pfizer, BMS, XCovery, Celegene, Roche/Genentech, Astra Zeneca/MedImmune, Lilly, Gilead, Pharmacyclics, Exellxis, and Clovis. Dr. Daly has received grants from EMD Serono. All other authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2018 International Association for the Study of Lung Cancer",

year = "2018",

month = jun,

doi = "10.1016/j.jtho.2018.04.002",

language = "English (US)",

volume = "13",

pages = "767--778",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "6",

}

TY - JOUR

T1 - Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017

AU - Donington, Jessica S.

AU - Kim, Young Tae

AU - Tong, Betty

AU - Moreira, Andre L.

AU - Bessich, Jamie

AU - Weiss, Kathleen D.

AU - Colson, Yolonda L.

AU - Wigle, Dennis

AU - Osarogiagbon, Raymond U.

AU - Zweig, Jeffrey

AU - Wakelee, Heather

AU - Blasberg, Justin

AU - Daly, Megan

AU - Backhus, Leah

AU - Van Schil, Paul

N1 - Funding Information: Disclosure: Dr. Donington has received personal fees from Astra Zeneca. Dr. Tong has received personal fees from Medtronic. Dr. Moreira has received support from Genentech. Drs. Weiss and Colson have received grants from the National Institutes of Health, Brigham and Women’s Hospital Advanced Training in Surgical Oncology T32 Fellowship (5T32CA009535). Dr. Osarogiagbon has a patent application pending for a lymph node specimen collection kit. Dr. Wakelee has received fees from Peregrine, ACEA, Novartis, Pfizer, Roche/Genetech, and Helsinn; and has received grants from Novartis, Pfizer, BMS, XCovery, Celegene, Roche/Genentech, Astra Zeneca/MedImmune, Lilly, Gilead, Pharmacyclics, Exellxis, and Clovis. Dr. Daly has received grants from EMD Serono. All other authors declare no conflict of interest. Publisher Copyright: © 2018 International Association for the Study of Lung Cancer

PY - 2018/6

Y1 - 2018/6

N2 - The landscape of care for early-stage non–small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. We have an increased understanding of the diversity of early-stage disease and how to better tailor treatments to make them more tolerable without impacting efficacy. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. The source for information includes large academic meetings, the published literature, or novel unpublished data from other international oncology assemblies.

AB - The landscape of care for early-stage non–small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. We have an increased understanding of the diversity of early-stage disease and how to better tailor treatments to make them more tolerable without impacting efficacy. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. The source for information includes large academic meetings, the published literature, or novel unpublished data from other international oncology assemblies.

KW - Adjuvant therapy

KW - Intraoperative lymph node evaluation

KW - Non–small cell lung cancer

KW - Pathology

KW - Radiotherapy

KW - Screening

KW - Sublobar resection

KW - Surgery

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=85047339543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047339543&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.04.002

DO - 10.1016/j.jtho.2018.04.002

M3 - Review article

C2 - 29654928

AN - SCOPUS:85047339543

SN - 1556-0864

VL - 13

SP - 767

EP - 778

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 6

ER -

Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this